Skip Navigation



Annals of Oncology Advance Access published online on June 2, 2009
Annals of Oncology, doi:10.1093/annonc/mdp029
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
20/9/1589    most recent
mdp029v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Jarnagin, W. R.
Right arrow Articles by Kemeny, N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Jarnagin, W. R.
Right arrow Articles by Kemeny, N.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2009. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oxfordjournals.org

Regional chemotherapy for unresectable primary liver cancer: results of a phase II clinical trial and assessment of DCE-MRI as a biomarker of survival

W. R. Jarnagin1,*, L. H. Schwartz2, D. H. Gultekin2, M. Gönen3, D. Haviland4, J. Shia5, M. D'Angelica1, Y. Fong1, R. DeMatteo1, A. Tse4, L. H. Blumgart1 and N. Kemeny4

1 Department of Surgery
2 Department of Radiology
3 Department of Epidemiology and Biostatistics
4 Department of Medical Oncology
5 Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York, NY, USA

* Correspondence to: Dr W. R. Jarnagin, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA. Tel: +1-212-639-7601; Fax: +1-212-639-4031; E-mail: jarnagiw{at}mskcc.org

Background: This study reports the results of hepatic arterial infusion (HAI) with floxuridine (FUDR) and dexamethasone (dex) in patients with unresectable intrahepatic cholangiocarcinoma (ICC) or hepatocellular carcinoma (HCC) and investigates dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) assessment of tumor vascularity as a biomarker of outcome.

Patients and methods: Thirty-four unresectable patients (26 ICC and eight HCC) were treated with HAI FUDR/dex. Radiologic dynamic and pharmacokinetic parameters related to tumor perfusion were analyzed and correlated with response and survival.

Results: Partial responses were seen in 16 patients (47.1%); time to progression and response duration were 7.4 and 11.9 months, respectively. Median follow-up and median survival were 35 and 29.5 months, respectively; 2-year survival was 67%. DCE-MRI data showed that patients with pretreatment integrated area under the concentration curve of gadolinium contrast over 180 s (AUC 180) >34.2 mM·s had a longer median survival than those with AUC 180 <34 mM·s (35.1 versus 19.1 months, P = 0.002). Decreased volume transfer exchange between the vascular space and extracellular extravascular space (–{Delta}Ktrans) and the corresponding rate constant (–{Delta}kep) on the first post-treatment scan both predicted survival.

Conclusions: In patients with unresectable primary liver cancer, HAI therapy can be effective and safe. Pretreatment and early post-treatment changes in tumor perfusion characteristics may predict treatment outcome.

DCE-MRI, HAI FUDR, hepatocellular carcinoma, intrahepatic cholangiocarcinoma

Received for publication November 7, 2008. Revision received January 15, 2009. Accepted for publication January 23, 2009.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.